Louis W. Sullivan - 30 Apr 2025 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Reporting relationship: Director
Issuer ticker: EBS
Reported as of: 30 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 May 2025, 20:30:17 UTC
Prior SEC filing: 19 Dec 2024
Next SEC filing: 28 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Richard S. Lindahl, Attorney-in-fact

Key filing fact

Louis W. Sullivan filed Form 4 for Emergent BioSolutions Inc. (EBS) on 02 May 2025.

Key facts

This page summarizes Louis W. Sullivan's Form 4 filing for Emergent BioSolutions Inc. (EBS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 May 2025, 20:30.

Change

Previous filing in this sequence was filed on 19 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001193522 Primary reporting owner

SULLIVAN LOUIS W

Relationship: Director
Address: 300 PROFESSIONAL DR, GAITHERSBURG
Signature: /s/ Richard S. Lindahl, Attorney-in-fact
Signature date: 02 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EBS transaction

Common Stock

Award

Transaction value: $0
Shares: +34,403
Change %: +33%
Price: $0.000000
Shares after: 139,098
Date: 30 Apr 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EBS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +15,824
Change %: +61%
Price: $0.000000
Shares after: 41,572
Date: 30 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,824
Exercise price: $5.45
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

Footnote F2

Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

Footnote F3

The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.